Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 9426 - 9450 of 9507 in total
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Investigational
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
Investigational
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Investigational
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Investigational
Investigational
Investigational
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy...
Investigational
CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.
Investigational
Investigational
Tezampanel is an AMPA receptor antagonist.
Investigational
Investigational
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Investigational
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.
Investigational
Investigational
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Displaying drugs 9426 - 9450 of 9507 in total